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Introduction
Anemia is a common occurrence in the intensive care unit
(ICU), and blood transfusions are commonly used for the
treatment of anemia in critical care. A number of studies
[1–6] have documented the prevalence of anemia in critically
ill patients and the high rate of blood transfusions adminis-
tered in ICUs.
In 1995, Corwin and coworkers [1] examined red blood cell
(RBC) transfusion practice in the multidisciplinary ICU of their
tertiary care center. They reported that 85% of critically ill
patients with an ICU length of stay of greater than 1 week
received blood transfusions, with a mean of 9.5 ± 0.8 units
per patient. Particularly important is the fact that patients
were phlebotomized 61–70 ml/day on average, with phle-
botomy accounting for 49% of the variation in the amount of
blood transfused based on multiple regression analysis.
Moreover, no indication for blood transfusion was identified
for 29% of transfusion events. This study clearly documented
that the long-term ICU population received a large number of
blood transfusions, and that phlebotomy contributed signifi-
cantly to the need for these transfusions. There was no clear
indication for a large number of the transfusions given. Many
transfusions appear to be administered because of an arbi-
trary ‘transfusion trigger’ rather than a physiologic need for
blood. The authors concluded that blood conservation and
adherence to transfusion guidelines could significantly
reduce RBC transfusion in the ICU.
Two recent large prospective studies have examined the
prevalence of anemia in the ICU in Western Europe and in
the USA: the Anemia and Blood Transfusion in Critical Care
(ABC) trial [2] and the CRIT study [3], respectively. The ABC
trial [2], a prospective observational study, aimed to define
the incidence of anemia and the use of RBC transfusions in
critically ill patients and to explore the potential benefits and
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Abstract
Anemia is a common problem in critically ill patients. It is caused, in part, by blood loss related to
phlebotomy for diagnostic testing, occult gastrointestinal bleeding, renal replacement therapies,
surgical intervention, and traumatic injuries. Reduced red cell life span and nutritional deficiencies (iron,
folate, vitamin B12) may be other contributing factors. In addition, critically ill patients have impaired
erythropoiesis because of blunted endogenous erythropoietin production and the direct inhibitory
effects of inflammatory cytokines on red blood cell production by the bone marrow. Blood transfusions
are commonly utilized for treatment of anemia in critical care, resulting in high use of blood transfusions
in the intensive care unit (ICU). The percentage of patients transfused in the ICU is inversely related to
admission hemoglobin and directly related to age and severity of illness. Patients with an increased
length of stay in the ICU are also at increased risk for receiving blood transfusions. Studies are needed
to improve our understanding of the pathophysiology of ICU-acquired anemia, to determine the
efficacy of blood transfusions in critical care, and to investigate alternatives to blood transfusion for the
treatment of anemia in the ICU.
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risks associated with transfusion in the ICU. The study was
conducted in November 1999 and included 3534 patients
from 146 Western European ICUs. The mean hemoglobin
concentration at ICU admission was 11.3 ± 2.3 g/dl, with
29% of patients having a concentration of less than 10 g/dl.
The transfusion rate during the ICU period for the entire
cohort was 37.0% (1307/3534). Patients admitted for emer-
gency surgery were transfused more frequently (57.5%), fol-
lowed by those admitted for trauma (48%), elective surgery
(42.1%), and medical reasons (32%). Older patients and
those with a longer length of stay in the ICU were more com-
monly transfused. Of patients with an ICU length of stay
longer than 7 days, 73% received a blood transfusion. The
overall mean pretransfusion hemoglobin was 8.4 ± 1.3 g/dl in
this European study.
A similar prospective, multicenter, observational, cohort study
conducted in the USA, the CRIT study [3], enrolled 4892
patients (August 2000–April 2001) from 284 ICUs. The goal
of the CRIT study was to quantify the incidence of anemia and
RBC transfusion practice in critically ill patients and to
examine the relationship of anemia and RBC transfusion to
clinical outcomes. Mean baseline hemoglobin concentration
on admission to the ICU was 11.0 ± 2.4 g/dl, and mean hemo-
globin decreased to 9.8 ± 1.4 g/dl by the end of the study
(P < 0.0045). Of patients evaluated, 44% were transfused
(mean 4.6 ± 4.9 units) during their ICU stay. Patients with an
ICU length of stay of 7 days or longer were more commonly
transfused (63.0%) than were patients with an ICU length of
stay less than 7 days (33.4%; P < 0.0001). Mean pretransfu-
sion hemoglobin was 8.6 ± 1.7 g/dl in this US study.
A post-hoc analysis of the subset of trauma patients (n = 576)
from the CRIT study [4] documented a higher transfusion rate
in critically ill trauma patients. Mean baseline hemoglobin was
11.1 ± 2.4 g/dl and patients remained anemic throughout the
study either with or without transfusion; 55.4% of patients
were transfused (mean 5.8 ± 5.5 units) during the ICU stay
and 43.8% of patients had an ICU length of stay of 7 days or
longer. Mean pretransfusion hemoglobin was 8.9 ± 1.8 g/dl.
When compared with the full ICU study population, patients
in the trauma subset were more likely to be transfused
(55.4% versus 44%) and received an average of 1 additional
unit of blood. This study confirmed that anemia is common in
critically injured trauma patients and persists throughout the
duration of critical illness, resulting in a large number of RBC
transfusions during patients’ ICU course.
Another recent prospective observational study assessed
current transfusion practice in critically ill patients in the UK
[5]. In that study it was found that 666 of 1247 (53%) con-
secutive critically ill patients received RBC transfusions.
Transfused patients had significantly higher ICU mortality but
they also had higher Acute Physiology and Chronic Health
Evaluation (APACHE) II scores and longer durations of stay.
The average pretransfusion hemoglobin concentration was
below 9 g/dl in 75% of transfusion episodes. The common
indications for transfusion were low hemoglobin (72%) and
hemorrhage (25%). This study documented the high use of
RBC transfusions in critically ill patients and confirmed that
anemia was the most common reason for blood transfusion in
critical care.
These epidemiological studies examining anemia in the ICU in
different countries have revealed a number of similarities
(Table 1). First, the vast majority of critically ill patients have
anemia on admission to the ICU, with hemoglobin concentra-
tions below the normal range. Second, the transfusion trigger
(i.e. pretransfusion hemoglobin) in all of these studies was
documented to be a hemoglobin of approximately 8.5 g/dl,
demonstrating a slight reduction in transfusion trigger from
prior published reports. Third, in the studies reviewed, RBC
transfusion rates were increased in patients with a prolonged
length of stay in the ICU and increased age. Finally, the most
common indication for RBC transfusion in the ICU was the
treatment of anemia.
Nguyen and colleagues [6] evaluated the time course of
hemoglobin concentrations in nonbleeding ICU patients
(n=91) in a prospective, single-institution observational study
in a medical-surgical ICU. These patients had no evidence of
recent or active blood loss, no history of hematologic disease or
chronic renal failure, and no need for renal replacement therapy.
For the entire ICU stay, the fall in hemoglobin concentrations
(calculated from the mean of individual slopes of hemoglobin
concentrations over time) averaged 0.52 ± 0.69 g/dl per day.
For the 33 patients who remained in the ICU for longer than
3 days, this decline was larger for the first 3 days than for sub-
sequent days (0.66 ± 0.84 g/dl per day versus 0.12 ± 0.29 g/dl
per day; P < 0.01). After the third ICU day the change in hemo-
globin concentrations was inversely related to the severity of
the disease, as reflected by the APACHE II and the sepsis-
related organ failure assessment scores. Hemoglobin concen-
trations decreased by 0.44 ± 0.70 g/dl per day in the
nonseptic patients and 0.68 ± 0.66 g/dl per day in the septic
patients (P = 0.13). After the third ICU day, hemoglobin con-
centrations continued to decrease in the septic patients but not
in the nonseptic patients (–0.29 ± 0.19 versus 0.006 ± 0.3 g/dl
per day; P = 0.0016). The fall in hemoglobin concentrations
was not significantly related to the fluid balance. The authors
concluded that hemoglobin concentrations typically decline
by more than 0.5 g/dl per day during the first days of ICU stay
in nonbleeding patients. Beyond the third ICU day, hemoglo-
bin concentrations remained relatively constant in nonseptic
patients but continued to decrease in septic patients.
A small study conducted in medical ICU patients (n = 96)
similarly documented a high rate of anemia on admission to
the ICU and subsequent blood transfusions required for treat-
ment of anemia [7]. The median hemoglobin concentration
was 12.1 g/dl at admission and 11.2 g/dl at the end of the
ICU stay. A total of 74 patients (77%) suffered from anemiaS3
and received 257 RBC units, approximately half of which
were given within the first 5 days. Three patients who
received 19 RBC units were admitted with acute gastro-
intestinal bleeding, but in the remainder a median total blood
loss of 128 ml/day was not (n=60) or not solely (n=11) a
result of overt bleeding. The authors concluded that anemia is
frequent and results in high requirement for RBC transfusions
in the medical intensive care setting.
Variability in intensive care unit transfusion
practice
There is evidence to suggest that there still exists consider-
able variation in RBC transfusion practices in critical care.
The impact of anemia on outcome in critically ill patients and
the optimal therapy for anemia have not been fully defined.
The ability of a patient to tolerate anemia depends on his or
her clinical condition and the presence of any significant
comorbidities; maintenance of circulating volume is of para-
mount importance. There is no universal transfusion trigger.
Current guidelines for critically ill and perioperative patients
advise that, at hemoglobin values of under 7 g/dl, RBC trans-
fusion is strongly indicated, whereas at hemoglobin values in
excess of 10 g/dl blood transfusion is unjustified. For patients
with hemoglobin values in the range of 7–10 g/dl, the transfu-
sion trigger should be based on clinical indicators. Uncertain-
ties still exist concerning the most appropriate hemoglobin
concentration for patients with significant cardiorespiratory
disease [8].
A Canadian scenario-based national survey was sent to criti-
cal care practitioners (n = 254) to characterize the contem-
porary RBC transfusion practice in the critically ill and to
define clinical factors that influence these practices [9]. Par-
ticipants were asked a series of questions after reviewing four
separate clinical scenarios. A 76% response rate was
achieved. The primary specialty of most respondents was
internal medicine (56%); the respondents were in practice for
an average of 8.4 ± 5.7 years and worked most often in com-
bined medical/surgical ICUs (82%). Baseline hemoglobin
transfusion thresholds averaged from 8.3 ± 1.0 g/dl in a sce-
nario involving a young stable trauma victim to 9.5 ± 1.0 g/dl
for an older patient after gastrointestinal bleeding. Transfu-
sion thresholds differed significantly (P < 0.0001) between
each of the four separate scenarios. With the exception of
congestive heart failure (P > 0.05), all clinical factors (includ-
ing age, APACHE II score, preoperative status, hypoxemia,
shock, lactic acidosis, coronary ischemia, and chronic
anemia) significantly modified the transfusion thresholds
(P < 0.0001). A statistically significant (P < 0.01) difference
in baseline transfusion thresholds was noted across four
major regions (with a maximum of five academic centers per
region) of the country. This survey confirmed significant vari-
ability in critical care transfusion practice among intensivists
in Canada.
Hebert and coworkers [10] subsequently examined blood
use in 5298 consecutive patients admitted to six tertiary level
ICUs. The overall number of transfusions per patient day in
the ICU averaged 0.95 ± 1.39 and ranged from 0.82 ± 1.69
to 1.08 ± 1.27 between institutions (P < 0.001). Independent
predictors of transfusion thresholds (pretransfusion hemoglo-
bin concentrations) included patient age, admission APACHE II
score, and institution (P < 0.0001). A very significant institu-
tion effect (P < 0.0001) persisted even after multivariate
adjustments for age and for APACHE II score, and within four
diagnostic categories (cardiovascular disease, respiratory
failure, major surgery and trauma; P < 0.0001). That study
also documented that 35% (202 out of 576) of pretransfusion
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Table 1
Results of epidemiologic studies on anemia and blood transfusions in critical care
North Thames 
TRICC Blood  Interest 
ABC Trial [2]  CRIT Study [3]  Investigators [9]  Group [5] 
(Western Europe) (USA) (Canada) (UK)
n 3534 4892 5298 1247
Mean admission hemoglobin (g/dl) 11.3 ± 2.3 11.0 ± 2.4 9.9 ± 2.2 –
Percentage of patients transfused in ICU 37.0% 44.1% 25% 53.4%
Mean transfusions per patient (units) 4.8 ± 5.2 4.6 ± 4.9 4.6 ± 6.7 5.7 ± 5.2
Mean pretransfusion hemoglobin (g/dl) 8.4 ± 1.3 8.6 ± 1.7 8.6 ± 1.3 8.5 ± 1.4
Mean ICU length of stay (days) 4.5 7.4 ± 7.3 4.8 ± 12.6 –
ICU mortality 13.5% 13.0% 22% 21.5%
Hospital mortality 20.2% 17.6% – –
Admission APACHE II (mean) 14.8 ± 7.9 19.7 ± 8.2 18 ± 11 18.1 ± 9.1
Data are expressed as mean ± standard deviation. ABC, Anemia and Blood Transfusion in Critical Care; APACHE, Acute Physiology and Chronic
Health Evaluation; ICU, intensive care unit; TRICC, Transfusion Requirements in Critical Care.S4
hemoglobin concentrations were in the range 9.5–10.5 g/dl,
and 80% of the orders were for 2 units of blood. The most
frequent reasons for administering red cells were acute
bleeding (35%) and augmentation of oxygen delivery (25%).
This study similarly showed that there was significant institu-
tional variation in critical care transfusion practice, with many
intensivists still adhering to a 10 g/dl threshold and transfus-
ing multiple units of blood despite published guidelines to the
contrary. This analysis spurred the conduct of the subsequent
prospective studies to define optimal practice regarding
treatment of anemia with blood transfusion in the critically ill.
Efficacy of blood transfusions in critical care
In 1995, a pilot study [11] was reported by the Canadian
Critical Care Trials Group, which evaluated the effects of a
restrictive and a liberal RBC transfusion strategy on mortality
and morbidity in critically ill patients. This multicenter,
prospective, randomized clinical trial enrolled 69 normo-
volemic critically ill patients admitted to one of five tertiary
level ICUs with hemoglobin values less than 9 g/dl within
72 hours of admission. Patients were randomly assigned to
one of two RBC transfusion strategies. Hemoglobin values
were maintained between 10 and 12 g/dl in the liberal trans-
fusion group and between 7 and 9 g/dl in the restrictive
group. Daily hemoglobin values averaged 9 g/dl in the restric-
tive group and 10.9 g/dl in the liberal group (P < 0.001). The
restrictive group received 2.5 units per patient compared with
4.8 units per patient in the liberal group. This represented a
48% relative decrease (P < 0.001) in RBC units transfused
per patient. No differences in 30-day mortality (24% versus
25%; 95% confidence interval [CI] –19% to +21%), ICU
mortality (P = 0.76) and 120-day mortality (P > 0.99) were
noted. In addition, survival analysis comparing time until death
in both groups did not reveal any significant difference
(P = 0.93) between groups. Organ dysfunction scores were
also similar (P = 0.44). In this small randomized trial, neither
mortality nor the development of organ dysfunction was
affected by the transfusion strategy, which suggested that a
more restrictive approach to the transfusion of RBCs may be
safe in critically ill patients.
The results of this pilot study were validated in a subsequent
large, prospective, multicenter trial (Transfusion Require-
ments in Critical Care [TRICC]) conducted by the Canadian
Critical Care Trials Group [12]. Using the same experimental
design as the pilot study described above, 838 critically ill
patients were randomly assigned to a restrictive or liberal
transfusion strategy. Although the 30-day mortality rates were
similar in the two groups (Table 2), the hospital mortality rate
was significantly lower in the restrictive strategy group
(22.2% versus 28.1%; P = 0.05). Mortality rates were also
significantly lower with the restrictive transfusion strategy
among patients who were less acutely ill (APACHE II
score = 20: 8.7% in restrictive group versus 16.1% in liberal
group; P = 0.03) and among patients who were younger than
55 years old (5.7% versus 13.0%, respectively; P = 0.02).
That study documented that a restrictive strategy of RBC
transfusion in critically ill patients was at least as effective as,
and possibly superior to, a liberal transfusion strategy, with
the possible exception of patients with acute myocardial
infarction and unstable angina.
Similar findings were identified in the noninterventional ABC
trial conducted in Western Europe [2]. Both ICU and overall
mortality rates were significantly higher in patients who were
transfused (ICU mortality 18.5% versus 10.1%, χ2 = 50.1,
P < 0.001; overall mortality 29.0% versus 14.9%, χ2 = 88.1,
P < 0.001). For similar degrees of organ dysfunction, patients
who had a transfusion had a higher mortality rate. For
matched patients in the propensity analysis, the 28-day mor-
tality was 22.7% among patients with transfusions and
17.1% among those without (P = 0.02); the Kaplan–Meier
log-rank test confirmed this difference. This large epidemio-
logic study provided evidence of an association between
blood transfusions and diminished organ function, as well as
between transfusions and mortality.
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Table 2
Results of the Transfusion Requirements in Critical Care (TRICC) trial comparing a restrictive versus liberal transfusion strategy in
critically ill patients
Restrictive Liberal 
(hemoglobin maintained  (hemoglobin maintained 
between 7 and 9 g/dl) between 10 and 12 g/dl) P
n 418 420 –
Mortality, 30-day 18.7% 23.3% 0.11
Mortality, ICU 13.4% 16.2% 0.29
Mortality, hospital 22.2% 28.1% 0.05
Mean hemoglobin (g/dl) 8.5 ± 0.7 10.7 ± 0.7 <0.01
Mean blood transfusion (units) 2.6 ± 4.1 5.6 ± 5.3 <0.01
Data are expressed as mean ± standard deviation. ICU, intensive care unit. Adapted from Hebert and coworkers [12].S5
Significant concern exists among intensivists regarding
whether critically ill patients with cardiovascular disease can
tolerate anemia in the face of limited cardiac reserve. The
cohort of patients (n = 357) with pre-existing cardiovascular
disease in the TRICC trial was analyzed post hoc to address
this question [13]. Overall, all mortality rates were similar in
both study groups, including 30-day (23% versus 23%;
P = 1.00), 60-day, hospital, and ICU rates (Table 3). In a
stepwise logistic regression analysis, the transfusion strategy
did not emerge as having an important influence on 30-day
outcome. Furthermore, changes in multiple organ dysfunction
from baseline scores were significantly less in the restrictive
transfusion group overall (0.2 ± 4.2 versus 1.3 ± 4.4;
P = 0.02). In the 257 patients with severe ischemic heart
disease there were no statistically significant differences in all
survival measures, but this was the only subgroup in which the
restrictive group had lower but nonsignificant absolute survival
rates compared with the patients in the liberal group. The
authors concluded that a restrictive RBC transfusion strategy
generally appeared to be safe in most critically ill patients with
cardiovascular disease, with the possible exception of patients
with acute myocardial infarcts and unstable angina.
The significant increase in hospital mortality identified in the
liberal transfusion strategy group in the TRICC trial is of
concern. The increased mortality rate in patients in the liberal
group was not solely accounted for by the higher incidence
of pulmonary edema in this group. Other potential adverse
effects related to allogeneic blood transfusion have been
identified, including increased risk for nosocomial infection
[14], inflammatory response [15], pulmonary and systemic
vasoconstriction related to age of blood and nitric oxide
binding [16,17], and immunosuppression [18].
An additional post-hoc cohort analysis of the TRICC trial was
performed in patients requiring mechanical ventilation
(n=713) in order to address the controversy over whether
the use of allogeneic blood transfusion for treatment of
anemia in these patients improves the weaning process [19].
No difference in mean duration of mechanical ventilation or
mean ventilator-free days was identified between the restric-
tive transfusion strategy and the liberal transfusion strategy
group (Table 4). Of the patients in the restrictive-strategy
group, 82% were considered successfully weaned and extu-
bated for at least 24 hours, as compared with 78% for the
liberal-strategy group (P = 0.19). The relative risk (RR) for
extubation success in the restrictive group compared with the
liberal group, adjusted for the confounding effects of age,
APACHE II score, and comorbid illness, was 1.07 (95% CI
0.91–1.26;  P = 0.43). The adjusted RR for extubation
success associated with restrictive transfusion in the 219
patients who received mechanical ventilation for more than
7 days was 1.11 (95% CI 0.84–1.45; P = 0.47). In that study
there was no evidence that a liberal RBC transfusion strategy
decreased the duration of mechanical ventilation in a hetero-
geneous population of critically ill patients.
The TRICC trial clearly established the safety of a restrictive
blood transfusion strategy, suggesting that physicians could
easily minimize exposure to allogeneic RBCs by lowering
their transfusion threshold. A recent study investigated RBC
transfusion practice since publication of the TRICC trial to
determine its impact in a large Scottish teaching hospital ICU
[20]. Prospective data were collected daily for 6 months on
hemoglobin concentrations, RBC transfusions, and indica-
tions for transfusions throughout the ICU stay for all patients
with an ICU length of stay in excess of 24 hours. A total of
176 patients who utilized 1237 ICU days were studied. Of
these, 52% received RBC transfusions. A hemoglobin con-
centration of 9 g/dl or less was measured in 55% of patients;
this occurred by day 1 and day 2 in 52% and 77% of these
cases, respectively. Overall, the hemoglobin concentration
was 9 g/dl or less for 45% of all patient days. Mean RBC
transfusion was 3.1 units per ICU admission (0.47 units/
patient-day). Only 18% of transfusion episodes were required
for hemorrhage. For nonhemorrhage transfusion episodes,
the median pretransfusion hemoglobin concentration was
7.8 g/dl (interquartile range 7.4–8.4 g/dl), and 64% of trans-
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Table 3
Results of the Transfusion Requirements in Critical Care (TRICC) trial in patients with cardiovascular disease
Restrictive Liberal P
n 160 197 –
Mortality, 30-day 23% 23% 1.0
Mortality, ICU 19% 16% 0.49
Mortality, hospital 27% 28% 0.81
MODS, change from baseline scores 0.23 ± 4.2 1.28 ± 4.4  0.023
Mean hemoglobin (g/dl) 8.5 ± 0.62 10.3 ± 0.67 <0.01
Mean blood transfusion (units) 2.4 ± 4.1 5.2 ± 5.0 <0.01
Data are expressed as mean ± standard deviation. ICU, intensive care unit; MODS, multiple organ dysfunction score. Adapted from Hebert and
coworkers [13].S6
fusion episodes were for 2 units. Clinicians practicing in this
ICU were conservative, in keeping with recent transfusion
guidelines, but deviated from the TRICC protocol by transfus-
ing at hemoglobin concentrations of between 7 and 9 g/dl,
rather than below 7 g/dl, and by prescribing 2 unit transfusions.
Systematic review of blood transfusion
Most clinical practice guidelines recommend restrictive red
cell transfusion practices with the goal of minimizing exposure
to allogeneic blood (from an unrelated donor). A recent
Cochrane review [21,22] compared clinical outcomes in
patients randomized to restrictive versus liberal transfusion
thresholds or triggers. This review included controlled trials in
which patients were randomly assigned to an intervention
group or to a control group. Trials were included that
assigned the intervention groups on the basis of a clear trans-
fusion ‘trigger’, described as a hemoglobin or hematocrit level
below which a RBC transfusion was to be administered. Rel-
ative risks for requiring allogeneic blood transfusion, trans-
fused blood volumes, and other clinical outcomes were
pooled across trials using a random effects model. Eligibility
of studies was assessed by two independent raters, with dis-
agreements resolved by consensus. Disagreements not
resolved by consensus were referred to a third party for
review. Two raters assessed the methodologic quality of the
trials modified from the methods of Schultz [23]. Ten trials
were identified that reported outcomes for a total of 1780
patients. Restrictive transfusion strategies reduced the risk
for receiving RBC transfusion by a relative 42% (RR 0.58,
95% CI 0.47–0.71). This was equivalent to an average
absolute risk reduction of 40% (95% CI 24–56%). The
volume of RBCs transfused was reduced on average by 0.93
units (95% CI 0.36–1.5 units) and hematocrit values were
5.6% lower (95% CI 3.5–7.7%). However, heterogeneity
between these trials was statistically significant
(P < 0.00001) for these outcomes. Mortality, rates of cardiac
events, morbidity, and length of hospital stay were unaffected,
and trials were of poor methodologic quality. This systematic
review concluded that limited published evidence supports
the use of restrictive transfusion triggers in patients who are
free from serious cardiac disease. However, most of the data
on clinical outcomes were generated by a single trial. The
effects of conservative transfusion triggers on functional
status, morbidity, and mortality, particularly in patients with
cardiac disease, have not been evaluated and need to be
tested in further large clinical trials.
The published evidence considering RBC transfusions in crit-
ical care therefore indicates that a target range of 7–9 g/dl
hemoglobin is at least as safe as, and may even be superior
to, a more liberal transfusion strategy. However, the optimal
transfusion trigger in relation to individual patient comorbidi-
ties requires further investigation. Hemoglobin-based oxygen
carriers and recombinant erythropoietin are promising treat-
ment options for anemia in critical care that are currently
under active investigation.
Strategies to prevent anemia in the intensive
care unit
Rigorous strategies of blood conservation may help to avoid
transfusions in the critical care setting. It has been clearly
documented that, for diagnostic laboratory testing in the ICU,
phlebotomy contributes significantly to blood loss in critically
ill patients. In the 1995 study conducted by Corwin and col-
leagues [1], patients receiving blood transfusions were phle-
botomized an average of 61–70 ml/day. That study
documented that phlebotomy accounted for 49% of the varia-
tion in the amount of RBCs transfused in critically ill patients.
More recent studies have documented a reduction in blood
loss related to phlebotomy in the ICU. A prospective study in
a medical ICU examined phlebotomy volume in 96 medical
ICU patients with ICU length of stay greater than 3 days [7].
Diagnostic blood loss declined from a median of 41 ml on
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Table 4
Results of the Transfusion Requirements in Critical Care (TRICC) trial in patients requiring mechanical ventilation
Restrictive Liberal P
n 357 356 –
Mortality, 30-day 21.3% 26.4% 0.11
Mortality, ICU 16% 19% 0.38
Mortality, hospital 25% 31% 0.07
Mean ventilator days 8.3 ± 8.1 8.8 ± 8.7  0.48
Mean ventilator-free days 17.5 ± 10.9 16.1 ± 11.4 0.09
Successful wean rates 82% 78% 0.19
Mean hemoglobin (g/dl) 8.4 ± 0.62 10.4 ± 0.71 <0.01
Mean blood transfusion (units) 2.7 ± 4.0 5.5 ± 5.1 <0.01
Data are expressed as mean ± standard deviation. ICU, intensive care unit. Adapted from Hebert and coworkers [19].S7
day 1 to less than 20 ml after 3 weeks and contributed 17%
(median) to total blood loss. Acute renal failure, fatal
outcome, and a Simplified Acute Physiology Score greater
than 38 on admission were associated with 5.8-fold, 7.0-fold,
and 2.8-fold increases in total blood loss, respectively.
In the ABC trial [2], a prospective, observational blood sam-
pling study was conducted in 1136 patients from 145
Western European ICUs. Frequency of blood drawing and
associated volume of blood drawn was collected over a 24-
hour period. The mean ± standard deviation volume per blood
draw was 10.3 ± 6.6 ml, with an average total volume of
41.1 ± 39.7 ml during the 24-hour period. There was a posi-
tive correlation between organ dysfunction and the number of
blood draws (r = 0.34;  P < 0.001) and total volume drawn
(r = 0.28; P < 0.001). In their single institution study, Nguyen
and colleagues [6] also documented that the mean volume of
blood drawn daily for laboratory studies was 40.3 ± 15.4 ml
(49.0 ± 11.3 ml in the septic patients and 36.7 ± 14.9 ml in
the nonseptic patients; P = 0.04).
The use of a blood conservation device to minimize diagnos-
tic phlebotomy blood loss in critically ill patients has been
documented to be efficacious. A prospective, randomized,
controlled trial in 100 medical ICU patients confirmed that a
device incorporated into the arterial pressure monitoring
system resulted in significant blood conservation [24]. The
volume of blood drawn and discarded from arterial catheters
was significantly lower in the blood conservation group
(blood conservation device 5.7 ± 7.5 ml control 96.4 ± 88.5 ml;
P < 0.0001), as was the total volume of blood discarded
(blood conservation device 19.4 ± 47.4 ml, control
103.5 ± 99.9 ml; P < 0.0001). Mean hemoglobin concentra-
tion on admission was similar in the two groups (blood
conservation device group 11.8 ± 2.5 g/dl, control group
12.6 ± 2.3 g/dl). Although the mean hemoglobin concentra-
tion was higher in the blood conservation group after 6 days,
statistical significance was not achieved until 9.5 days of ICU
care. The mean change in hemoglobin concentration (overall
1.2 ± 2.2 g/dl) during the study represents a statistically sig-
nificant (P < 0.0001) decrease of 9.7%. Univariate and multi-
ple regression analyses demonstrated discarded blood
volume to be a significant and independent predictor of the
decline in hemoglobin concentration.
A recent postal survey of arterial blood sampling practices in
280 ICUs throughout England and Wales found that very few
measures were taken to reduce diagnostic blood loss from
arterial sampling in adult intensive care patients [25]. The
average volume of blood withdrawn to clear the arterial line
before sampling was 3.2 ml, which was subsequently
returned to the patient in only 18.4% of ICUs. Specific mea-
sures to reduce the blood sample size by the routine use of
pediatric sample tubes in adult patients occurred in only
9.3% of ICUs. In pediatric ICUs, the average volume with-
drawn was 1.9 ml, which was routinely returned in 67% of
units. These aspects of arterial blood sampling practices
identified in the survey contribute to iatrogenic anemia in
intensive care patients.
Any strategy to reduce blood loss related to diagnostic phle-
botomy, including use of pediatric tubes, low-volume adult
tubes, and blood conservation devices, should be imple-
mented in as many ICUs as possible. These simple preventive
strategies can have a significant impact on reducing the inci-
dence of anemia in ICUs and further reducing the need for
allogeneic blood transfusion in critical care.
Competing interests
LMN is a consultant for Ortho Biotech Products, L.P.
References
1. Corwin HL, Parsonnet KC, Gettinger A: RBC transfusion in the
ICU. Is there a reason? Chest 1995, 108:767-771.
2. Vincent JL, Baron J-F, Reinhart K, Gattinoni L, Thijs L, Webb A,
Meier-Hellmann A, Nollet G, Peres-Bota D: Anemia and blood
transfusion in critically ill patients. JAMA 2002, 288:1499-1507.
3. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E,
MacIntyre NR, Shabot M, Duh M-S, Shapiro MJ: The CRIT study:
Anemia and blood transfusion in the critically ill: current clini-
cal practice in the United States. Crit Care Med 2004, 32:39-52.
4. Shapiro MJ, Gettinger A, Corwin HL, Napolitano L, Levy M,
Abraham E, Fink MP, Macintyre N, Pearl RG, Shabot MM: Anemia
and blood transfusion in trauma patients admitted to the
intensive care unit. J Trauma 2003, 55:269-274.
5. Rao MP, Boralessa H, Morgan C, Soni N, Goldhill DR, Brett SJ,
Boralessa H, Contreras M: Blood component use in critically ill
patients. Anaesthesia 2002, 57:530-534.
6. Nguyen BV, Bota DP, Melot C, Vincent JL: Time course of
hemoglobin concentrations in nonbleeding intensive care unit
patients. Crit Care Med 2003, 31:406-410.
7. von Ahsen N, Muller C, Serke S, Frei U, Eckardt K-U: Important
role of nondiagnostic blood loss blunted erythropoietic
response in the anemia of medical intensive care patients.
Crit Care Med 1999, 27:2630-2639.
8. McLellan SA, McClelland DB, Walsh TS: Anaemia and red
blood cell transfusion in the critically ill patient. Blood Rev
2003, 17:195-208.
9. Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajch-
man M, Pagliarello G, Schweitzer I, Calder L: A Canadian survey
of transfusion practices in critically ill patients. Crit Care Med
1998, 26:482-487.
10. Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajch-
man M, Pagliarello G, Sandham D, Schweitzer I, Boisvert D, Calder
L: Variation in red cell transfusion practice in the intensive care
unit: a multicentre cohort study. Crit Care 1999, 3:57-63.
11. Hebert PC, Wells G, Marshall J, Martin C, Tweeddale M,
Pagliarello G, Blajchman M: Transfusion requirements in critical
care: a pilot study. JAMA 1995, 273:1439-1444.
12. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C,
Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E: A multicen-
ter, randomized, controlled clinical trial of transfusion require-
ments in critical care. Transfusion Requirements in Critical
Care Investigators, Canadian Critical Care Trials Group. N
Engl J Med 1999, 340:409-417.
13. Hebert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall
J, Tweeddale M, Pagliarello G, Schweitzer I: Is a low transfusion
threshold safe in critically ill patients with cardiovascular dis-
eases? Crit Care Med 2001, 29:227-234.
14. Taylor RW, Manganaro L, O’Brien J, Trottier SJ, Parkar N, Vere-
makis C: Impact of allogenic packed red blood cell transfusion
on nosocomial infection rates in the critically ill patient. Crit
Care Med 2002, 30:2249-2254.
15. Johnson JL, Moore EE, Gonzalez RJ, Fedel N, Partrick DA, Silliman
CC: Alteration of the postinjury hyperinflammatory response
by means of resuscitation with a red cell substitute. J Trauma
2003, 54:133-139.
Available online http://ccforum.com/content/8/S2/S1S8
16. Fernandes CJ, Jr., Akamine N, De Marco FVC, De Souza JAM,
Lagudis S, Knobel E: Red blood cell transfusion does not
increase oxygen consumption in critically ill septic patients.
Crit Care 2001, 5:362-367.
17. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, III,
Schechter AN, Gladwin MT: Cell-free hemoglobin limits nitric
oxide bioavailability in sickle-cell disease. Nat Med 2002, 8:
1383-1389.
18. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfu-
sion medicine. First of two parts: blood transfusion. N Engl J
Med 1999, 340:438-447.
19. Hebert PC, Blajchman MA, Cook DJ, Yetisir E, Wells G, Marshall
J, Schweitzer I: Do blood transfusions improve outcomes
related to mechanical ventilation? Chest 2001,  119:1850-
1857.
20. Chohan SS, McArdle F, McClelland DB, Mackenzie SJ, Walsh TS:
Red cell transfusion practice following the transfusion
requirements in critical care (TRICC) study: prospective
observational cohort study in a large UK intensive care unit.
Vox Sang 2003, 84:211-218.
21. Hill SR, Carless PA, Henry DA, Carson JL, Hebert PC, McClelland
DB, Henderson KM: Transfusion thresholds and other strate-
gies for guiding allogeneic red blood cell transfusion.
Cochrane Lib 2002, CD002042.
22. Carson JL, Hill S, Carless P, Hebert P, Henry D: Transfusion trig-
gers: a systematic review of the literature. Transfus Med Rev
2002, 16:187-199.
23. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evi-
dence of bias. Dimensions of methodological quality associ-
ated with estimates of treatment effects in controlled trials.
JAMA 1995, 273:408-412.
24. Peruzzi WT, Parker MA, Lichtenthal PR, Cochran-Zull C, Toth B,
Blake M: A clinical evaluation of a blood conservation device
in medical intensive care unit patients. Crit Care Med 1993,
21:501-506.
25. O’Hare D, Chilvers RJ: Arterial blood sampling practices in
intensive care units in England and Wales. Anaesthesia 2001,
56:568-571.
Critical Care    June 2004 Vol 8 Suppl 2 Napolitano